Longevity & AgingResearch PaperOpen Access

IL-13 Fights Fatty Liver by Activating a Key Fat-Burning Signaling Chain

A newly identified immune-metabolic pathway shows interleukin-13 reduces liver fat accumulation, pointing to a novel therapeutic target for fatty liver disease.

Friday, October 2, 2026 0 views
Published in Cell Mol Gastroenterol Hepatol
Microscopic view of a hepatocyte with glowing fat droplets shrinking as luminous IL-13 molecules bind receptor proteins on the cell surface.

Summary

Fatty liver disease is tied to obesity and insulin resistance, and scientists want to know which immune signals protect the liver. This study looked at interleukin-13 (IL13), a protein usually linked to allergy and tissue repair. In 252 people with severe obesity, blood IL13 rose after three months of dieting or bariatric surgery and tracked with the metabolic hormones FGF19, FGF21, and IGF1. Mice lacking IL13 had disturbed liver fat metabolism, with lower fat-burning gene activity and lower omega-3 fats. In mouse liver cells loaded with fat, IL13 cut triglyceride buildup by activating a JNK–c-JUN–FOSL2 pathway that boosts fat burning and ketone production. FOSL2 was also elevated in livers of patients with fatty liver disease, which suggests this pathway could become a drug target.

Detailed Summary

Fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), tracks closely with obesity, insulin resistance, and type 2 diabetes. It develops when the liver takes in more fat, through de novo lipogenesis and free fatty acids from adipose tissue, than it can burn or export. Chronic low-grade inflammation helps drive progression to steatohepatitis and fibrosis. The authors asked whether interleukin-13 (IL13), a cytokine usually tied to allergy and tissue repair, acts as an immune regulator of liver lipid handling.

The human arm measured plasma IL13 in patients with class II or III obesity (BMI roughly 36 to 84 kg/m2) at baseline and after three months of bariatric surgery or a low-calorie diet. The baseline cohort included 188 women and 64 men. IL13 rose after the intervention in 108 women and 36 men, whether they had surgery or dieted. In women, baseline IL13 was higher at higher BMI. Patients with BMI of 50 or more had higher IL13 than those at 35 to 39.9 (P = .032 and .009), and those at 60 or more exceeded the 40 to 49.9 group (P = .019).

Baseline IL13 correlated positively with FGF19, FGF21, and IGF1, all hormones involved in metabolic and hepatic lipid regulation. Men showed the same pattern, though with smaller samples and more missing data. Alanine aminotransferase did not change over three months, and IL13 did not correlate with the albumin-bilirubin liver function score. Most patients had low fibrosis-risk scores, so the cohort was not one of advanced liver disease.

In 8-week-old female IL13-deficient mice on normal chow, body weight and serum ALT were normal, but serum triglycerides were elevated and liver phosphatidylserine was increased. Hepatic triglycerides and cholesterol did not differ at baseline. Liver polyunsaturated fats were lower, including alpha-linolenic acid (P = .0012), EPA (P = .0493), and linoleic acid (P = .0014). Lipogenesis genes (Fasn, Srebp1, Acly) and Pparγ were up, while the β-oxidation genes Pparα, Pparδ, and Pdk4 were down. Nuclear PPARδ staining was reduced.

In primary mouse hepatocytes loaded with 1 mM oleic acid, IL13 at 12.5 ng/mL, the upper range seen in patient plasma, reduced triglycerides and Oil Red O staining over 24 hours. It did not change triglycerides in non-fatty cells. IL13 raised Pparδ about 2-fold and Pparγ about 6-fold, lowered Dgat2, Ldlr, Cyp4a10, and Plin2, and slowed fatty acid uptake. It also induced Fosl2 and Jun, increased c-JUN phosphorylation, and promoted a c-JUN–FOSL2 complex that the JNK inhibitor SP600125 disrupted.

Silencing Il13ra1 or Fosl2 with siRNA, or inhibiting JNK, abolished IL13's lipid-lowering effect. FOSL2 overexpression alone reduced fat accumulation. The authors report that this pathway enhances β-oxidation and ketogenesis, and that FOSL2 was needed for maximal PPAR activity and was higher in liver tissue from patients with steatosis and steatohepatitis. Caveats: human data are correlational, the cohort was predominantly women with severe obesity and had no lean controls, in vitro work used mouse hepatocytes, and the FOSL2 knockdown was only partial.

Key Findings

  • Plasma IL13 increased after 3 months of bariatric surgery or a low-calorie diet in 108 women and 36 men with class II or III obesity.
  • Baseline IL13 was higher at higher BMI: BMI of 50 or more exceeded BMI 35 to 39.9 (P = .032 and .009), and BMI of 60 or more exceeded BMI 40 to 49.9 (P = .019).
  • Baseline IL13 correlated positively with FGF19, FGF21, and IGF1 in both sexes, but not with the ALBI liver function score.
  • IL13-deficient mice had elevated serum triglycerides, lower liver alpha-linolenic acid (P = .0012), EPA (P = .0493), and linoleic acid (P = .0014), and lower Pparα, Pparδ, and Pdk4 expression.
  • In oleic acid-loaded mouse hepatocytes, 12.5 ng/mL IL13 lowered triglycerides, increased Pparδ about 2-fold and Pparγ about 6-fold, and reduced fatty acid uptake.
  • Knocking down Il13ra1 (about 70% reduction) or Fosl2, or blocking JNK with SP600125, abolished IL13's lipid-lowering effect.
  • FOSL2 overexpression alone reduced oleic acid-induced fat accumulation, and FOSL2 was upregulated in livers of patients with steatosis and steatohepatitis.

Methodology

The study combined a human cohort of 252 patients with class II or III obesity (188 women, 64 men; plasma IL13 by ELISA at baseline and 3 months after bariatric surgery or a low-calorie diet), analysis of human liver biopsies, IL13-knockout versus wild-type mice, and primary mouse hepatocytes. Mouse work used 8-week-old female IL13−/− mice on normal chow, with lipidomics, PCR arrays, qRT-PCR, and immunohistochemistry. Hepatocytes were treated with IL13 and oleic acid, with siRNA knockdown, FOSL2 overexpression, immunoprecipitation, and JNK inhibition. Statistics included Wilcoxon matched-pairs tests, Pearson correlations, Student t tests, and two-way ANOVA.

Study Limitations

Human findings are correlational, with missing data for some measures, smaller male numbers, no lean control group, and a cohort of mostly low fibrosis-risk patients with unchanged ALT. The mechanistic work relied on mouse hepatocytes and female knockout mice, and Fosl2 knockdown was only partial (37% versus control). The excerpt provided was truncated, so conflict-of-interest disclosures and the full human liver biopsy analysis were not available for review.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: